Mindbreeze is named “a Leader” in the IDC MarketScape: Worldwide Dedicated Knowledge Management Solutions 2024 Vendor Assessment
5.12.2024 19:14:00 CET | Business Wire | Press release
Mindbreeze, a global leader in AI-powered enterprise intelligence, is named a Leader in the IDC MarketScape: Worldwide Dedicated Knowledge Management Solutions 2024 Vendor Assessment (doc #US51541224, December 2024).
Mindbreeze InSpire is transforming the future of enterprise intelligence, revolutionizing how organizations unlock the power of their information. Powered by advanced AI agents, it seamlessly integrates and analyzes structured and unstructured data from diverse systems, turning complexity into clarity. By creating dynamic insight journeys, Mindbreeze InSpire delivers hyper-relevant, context-aware insights tailored to employees’ unique roles and needs—enabling smarter decisions at every level. Beyond streamlining business process transformation, it empowers organizations to fully realize the value of their information ecosystems, driving innovation and securing a competitive edge in today’s fast-paced, data-driven world.
Therefore, “Consider Mindbreeze if you are a large enterprise customer looking for a knowledge management solution that can cater to business areas such as customer service, finance, legal, and HR. Pre-built search applications tailored to specific departments can enhance knowledge creation and search capabilities, while supporting broader business process transformations.”
“We are honored to be recognized as a 'Leader' in the IDC MarketScape: Worldwide Dedicated Knowledge Management Solutions 2024 Vendor Assessment,” says Daniel Fallmann, founder and CEO of Mindbreeze. “Our focus on delivering tailored insight journeys and flexible deployment options empowers businesses to unlock the true potential of generative AI use cases, seamlessly integrating them into daily workflows across the enterprise. This capability is key to driving business process transformation and automation, putting our customers in a winning position to thrive in a competitive landscape. We are proud of the pivotal role of our solutions in achieving these outcomes.”
Over 2,700 of the world's largest companies across a variety of industries rely on Mindbreeze to manage their information more efficiently and intelligently.
About the IDC MarketScape
IDC MarketScape vendor assessment model is designed to provide an overview of the competitive fitness of technology and service suppliers in a given market. The research utilizes a rigorous scoring methodology based on both qualitative and quantitative criteria that results in a single graphical illustration of each supplier’s position within a given market. IDC MarketScape provides a clear framework in which the product and service offerings, capabilities and strategies, and current and future market success factors of technology suppliers can be meaningfully compared. The framework also provides technology buyers with a 360-degree assessment of the strengths and weaknesses of current and prospective suppliers.
About Mindbreeze
Mindbreeze is a global leader in AI-powered enterprise intelligence, with locations in Europe and the US and a robust partner network worldwide. Mindbreeze InSpire redefines how organizations access and utilize information. Powered by advanced AI, it transforms complex data into actionable insights, seamlessly connecting and analyzing information across systems.
Unlike traditional solutions, our AI agents deliver hyper-relevant, context-aware insights tailored to unique business needs, enabling smarter, faster decision-making. With unmatched integration capabilities, enterprise-grade data security, and automation at its core, Mindbreeze InSpire maximizes the value of your information ecosystem while driving business innovation.
Trusted by industry leaders and recognized for our cutting-edge technology, Mindbreeze leads the way in unlocking new dimensions of enterprise intelligence.
Learn more at www.mindbreeze.com or follow us on LinkedIn and X @Mindbreeze.
View source version on businesswire.com: https://www.businesswire.com/news/home/20241205572409/en/
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
FPT Named an OpenAI Select Partner6.8.2026 02:00:00 CEST | Press release
Global IT corporation FPT today announced that it has been named an OpenAI Select Partner within the OpenAI Partner Network. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260805503787/en/ FPT Named an OpenAI Select Partner The OpenAI Partner Network is a global program for partners to build, sell, and deliver AI solutions with OpenAI. It brings together partners with deep industry expertise, delivery capabilities, and customer relationships while equipping them with resources, enablement, and support to help enterprises adopt OpenAI frontier models and products and turn them into measurable impact. As an OpenAI Select Partner, FPT will continue working with OpenAI to help organizations build, deploy, and scale AI solutions responsibly and effectively. This work will help organizations get more useful work from every token and stronger performance per dollar with GPT‑5.6, while using ChatGPT Work to turn ambitious goals into
U.S. FDA Approves Takeda’s ORZEYFUL™ (oveporexton), the First and Only Medicine to Treat the Underlying Cause of Narcolepsy Type 16.8.2026 00:10:00 CEST | Press release
Adults Taking ORZEYFUL Experienced Significant and Meaningful Improvements Across the Full Range of Symptoms of Narcolepsy Type 1 (NT1) in Clinical Trials Compared to Those on Placebo As a First-in-Class Orexin Treatment, ORZEYFUL has the Potential to Redefine NT1 Care Beyond Individual Symptoms Takeda is Advancing U.S. Launch Preparations and Expects to Make ORZEYFUL Available Following Completion of the Drug Enforcement Administration (DEA) Scheduling Process Takeda (TSE:4502/NYSE:TAK) announced that the U.S. Food and Drug Administration (FDA) approved ORZEYFUL™ (oveporexton), an oral orexin receptor 2 (OX2R) agonist, for the treatment of narcolepsy type 1 (NT1, narcolepsy with cataplexy) in adults.* The persistent 24-hour nature of NT1 is driven by orexin deficiency and can severely impact people’s lives. As a first-in-class orexin treatment, ORZEYFUL is the only medicine indicated in the U.S. to treat the disease holistically rather than individual symptoms. “The FDA approval of OR
Compass Pathways Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)5.8.2026 22:30:00 CEST | Press release
Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to unlocking urgently needed new treatment options in mental health care, announced today that Compass granted equity awards under the Compass Pathways plc 2026 Inducement Plan to fourteen newly hired non-executive employees. The equity awards were granted on August 3, 2026 and consisted of options to purchase an aggregate of 139,355 shares and restricted share units or, in the case of employees in the United Kingdom nominal cost options, covering an aggregate of 66,300 shares. The options have an exercise price per share equal to $11.25, the closing price of the Company’s American Depositary Shares on the Nasdaq Global Select Market on the grant date, and will vest over a four-year period with 25% vesting on the first anniversary of the date of the grant and the remaining 75% vesting in equal monthly installments over the three-year period thereafter, subject to each employee’s continued employment. The restricted
Clinilabs Announces Medical Leadership Appointments5.8.2026 16:05:00 CEST | Press release
Bob Dagher, M.D., Named Chief Medical Officer and Waqar Ahmed Siddiqui, M.D., Named Principal Investigator Clinilabs (“Clinilabs LLC”), a global, full-service contract research organization (CRO) specializing in central nervous system (CNS) drug and device development, today announced the appointments of Bob Dagher, M.D., as Chief Medical Officer and Waqar Ahmed Siddiqui, M.D., as Principal Investigator of the Company’s Eatontown, New Jersey Clinical Research Unit (CRU). Dr. Dagher will provide strategic and medical leadership across the organization, while Dr. Siddiqui will lead the execution of research projects at the Company’s CRU. Together, they will support the design, development, and execution of clinical programs for pharmaceutical, biotechnology, and medical device sponsors advancing innovative therapies for psychiatric, neurological, substance use, and rare CNS disorders. “Clinilabs has earned the trust of sponsors by combining deep scientific expertise, medical leadership,
Interactive Brokers Adds Brazilian Futures through Brazil’s B3 Exchange5.8.2026 16:00:00 CEST | Press release
Interactive Brokers (Nasdaq: IBKR), an automated global broker, today announced that eligible clients outside of Brazil can now trade Brazilian futures in addition to equities through the B3 exchange. Interactive Brokers was the first broker to provide international investors with streamlined, low-cost access to B3. Offering Brazilian futures and equities alongside products across more than 170 markets worldwide underscores IBKR’s commitment to broadening global market access and giving clients efficient, cost-effective ways to diversify through a single, unified platform. Access to B3 provides exposure to one of Latin America’s most active and liquid markets, providing long-term growth potential across multiple sectors and another way for investors to pursue emerging market opportunities. "Global investors deserve seamless, low-cost access to the world's most compelling markets, including emerging economies shaping tomorrow's financial landscape," said Milan Galik, Chief Executive Off
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom